BRVE(BRVE)
BRVE
Insider Transactions
Buys (12mo)
28
Sells (12mo)
5
Buy Value (12mo)
$184.50M
Net (12mo)
$184.50M
| Date | Insider | Title | Type | Price | Shares | Value | Owned After |
|---|---|---|---|---|---|---|---|
| Aug 7, 26 | Agarwala Vineeta | CTO | Sale | -- | -- | -- | 10.23M |
| Aug 7, 26 | AH Bio Fund IV, L.P. | 10 percent owner | Purchase | $18.00 | 1.10M | $19.80M | 10.23M |
| Aug 7, 26 | AH Bio Fund IV, L.P. | 10 percent owner | Purchase | -- | 9.13M | -- | 9.13M |
| Aug 7, 26 | AH Bio Fund IV, L.P. | 10 percent owner | Sale | -- | 40.00M | -- | -- |
| Aug 7, 26 | Chimovits Erez | CTO | Purchase | $18.00 | 1.67M | $30.00M | 11.90M |
| Aug 7, 26 | Chimovits Erez | CTO | Purchase | -- | 9.13M | -- | 10.24M |
| Aug 7, 26 | Chimovits Erez | CTO | Purchase | $18.00 | 273.33K | $4.92M | 273.33K |
| Aug 7, 26 | Chimovits Erez | CTO | Sale | -- | 40.00M | -- | -- |
| Aug 7, 26 | ORBIMED ADVISORS LLC | CTO | Purchase | $18.00 | 1.67M | $30.00M | 11.90M |
| Aug 7, 26 | ORBIMED ADVISORS LLC | CTO | Purchase | -- | 9.13M | -- | 10.24M |
| Aug 7, 26 | ORBIMED ADVISORS LLC | CTO | Purchase | $18.00 | 273.33K | $4.92M | 273.33K |
| Aug 7, 26 | ORBIMED ADVISORS LLC | CTO | Sale | -- | 40.00M | -- | -- |
| Aug 7, 26 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10 percent owner | Purchase | -- | 7.42M | -- | 7.42M |
| Aug 7, 26 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10 percent owner | Sale | -- | 32.50M | -- | -- |
| Aug 7, 26 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10 percent owner | Purchase | $18.00 | 1.92M | $34.56M | 11.64M |
| Aug 7, 26 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10 percent owner | Purchase | $18.00 | 1.68M | $30.24M | 10.19M |
| Aug 7, 26 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10 percent owner | Purchase | -- | 9.13M | -- | 9.72M |
| Aug 7, 26 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10 percent owner | Purchase | -- | 7.99M | -- | 8.51M |
| Aug 7, 26 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10 percent owner | Sale | -- | 35.00M | -- | -- |
| Aug 7, 26 | Rickey James Paul | CFO | Purchase | $18.00 | 27.78K | $499.99K | 520.93K |
| Aug 5, 26 | Rickey James Paul | CFO | Purchase | $18.00 | 300.00K | $5.40M | 300.00K |
| Aug 5, 26 | Lohoff Tim | CTO | Purchase | $18.00 | 30.00K | $540.00K | 30.00K |
| Aug 5, 26 | Chimovits Erez | CTO | Purchase | $18.00 | 30.00K | $540.00K | 30.00K |
| Aug 7, 26 | Viehbacher Christopher | CTO | Purchase | $18.00 | 83.33K | $1.50M | 609.52K |
| Aug 5, 26 | Viehbacher Christopher | CTO | Purchase | $18.00 | 30.00K | $540.00K | 30.00K |
| Aug 7, 26 | Malek David I | CTO | Purchase | $18.00 | 4.17K | $74.99K | 533.85K |
| Aug 5, 26 | Malek David I | CTO | Purchase | $18.00 | 30.00K | $540.00K | 30.00K |
| Aug 7, 26 | Anderson Michele A. | Officer | Purchase | $18.00 | 1.11K | $20.00K | 332.16K |
| Aug 5, 26 | Anderson Michele A. | Officer | Purchase | $18.00 | 300.00K | $5.40M | 300.00K |
| Aug 7, 26 | Murdoch Travis | CEO | Purchase | $18.00 | 83.33K | $1.50M | 2.94M |
| Aug 5, 26 | Murdoch Travis | CEO | Purchase | $19.80 | 550.00K | $10.89M | 550.00K |
| Aug 5, 26 | Bos Jasper | CTO | Purchase | $18.00 | 30.00K | $540.00K | 30.00K |
| Aug 5, 26 | Lubner David Charles | CTO | Purchase | $18.00 | 60.00K | $1.08M | 60.00K |
| Aug 7, 26 | Lubner David Charles | CTO | Purchase | $18.00 | 55.55K | $999.99K | 55.55K |
| Aug 5, 26 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10 percent owner | Sale | -- | 7.42M | -- | -- |
| Aug 5, 26 | ORBIMED ADVISORS LLC | CTO | Sale | -- | -- | -- | 1.10M |
| Aug 5, 26 | ORBIMED ADVISORS LLC | CTO | Sale | -- | 9.13M | -- | -- |
| Aug 5, 26 | AH Bio Fund IV, L.P. | 10 percent owner | Sale | -- | 9.13M | -- | -- |
| Aug 5, 26 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10 percent owner | Sale | -- | -- | -- | 588.13K |
| Aug 5, 26 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10 percent owner | Sale | -- | -- | -- | 514.61K |
| Aug 5, 26 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10 percent owner | Sale | -- | 7.99M | -- | -- |
| Aug 5, 26 | Rickey James Paul | CFO | Sale | -- | -- | -- | 493.15K |
| Aug 5, 26 | Rickey James Paul | CFO | Sale | -- | -- | -- | 91.32K |
| Aug 5, 26 | Viehbacher Christopher | CTO | Sale | -- | -- | -- | 526.19K |
| Aug 5, 26 | Viehbacher Christopher | CTO | Sale | -- | -- | -- | 150.34K |
| Aug 5, 26 | Bos Jasper | CTO | Sale | -- | -- | -- | -- |
| Aug 5, 26 | Lubner David Charles | CTO | Sale | -- | -- | -- | -- |
| Aug 5, 26 | Anderson Michele A. | Officer | Sale | -- | -- | -- | 331.05K |
| Aug 5, 26 | Anderson Michele A. | Officer | Sale | $3.07 | 70.78K | $217.28K | -- |
| Aug 5, 26 | Chimovits Erez | CTO | Sale | -- | -- | -- | 1.10M |
| Aug 5, 26 | Chimovits Erez | CTO | Sale | -- | 9.13M | -- | -- |
| Aug 5, 26 | Murdoch Travis | CEO | Sale | -- | -- | -- | 3.34M |
| Aug 5, 26 | Murdoch Travis | CEO | Sale | -- | -- | -- | 2.86M |
| Aug 5, 26 | Murdoch Travis | CEO | Sale | -- | -- | -- | 1.03M |
| Aug 5, 26 | Lohoff Tim | CTO | Sale | -- | -- | -- | -- |
| Aug 5, 26 | Malek David I | CTO | Sale | -- | -- | -- | 529.68K |
| Aug 5, 26 | Malek David I | CTO | Sale | -- | -- | -- | 239.73K |
| Aug 5, 26 | Coloma Jason V | CTO | Sale | -- | -- | -- | 913.24K |
| Aug 5, 26 | Coloma Jason V | CTO | Sale | -- | -- | -- | 93.61K |
Latest filing Checked hourly; insiders must file within 2 business days of a tradeAbout this data
Explore More
Stock Comparison
Compare equities side by side
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Market Movers
Today's biggest gainers and losers
Market Heatmap
Visual sector performance
